3-Hydroxyphenazepam
Appearance
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H10BrClN2O2 |
Molar mass | 365.61 g·mol−1 |
3D model (JSmol) | |
| |
|
3-Hydroxyphenazepam is a benzodiazepine with hypnotic, sedative, anxiolytic, and anticonvulsant properties.[1] It is an active metabolite of phenazepam,[1][2] as well as the active metabolite of the benzodiazepine prodrug cinazepam.[3] Relative to phenazepam, 3-hydroxyphenazepam has diminished myorelaxant properties, but is about equivalent in most other regards.[1] Like other benzodiazepines, 3-hydroxyphenazepam behaves as a positive allosteric modulator of the benzodiazepine site of the GABAA receptor with an EC50 value of 10.3 nM.[4][5][6] It has been sold as a designer drug.[7][8][9][10]
See also
[edit]- Lorazepam, licensed medication
- Nifoxipam
- Nitemazepam
References
[edit]- ^ a b c Valdman AV, ed. (31 May 1986). Drug dependence and emotional behavior: neurophysiological and neurochemical approaches. Consultants Bureau. ISBN 978-0-306-10984-3.
- ^ Komsta L, Waksmundzka-Hajnos M, Sherma J, eds. (20 December 2013). Thin Layer Chromatography in Drug Analysis. CRC Press. pp. 299–. ISBN 978-1-4665-0715-9.
- ^ Schukin SI, Zinkovsky VG, Zhuk OV (2011). "Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice". Pharmacological Reports. 63 (5): 1093–1100. doi:10.1016/s1734-1140(11)70628-4. PMID 22180351. S2CID 4744087.
- ^ "Phenazepam Pre-Review Report" (PDF). World Health Organization (WHO). November 2015.
- ^ Kopanitsa MV, Zbarska SM, Boychuk YA, Krishtal OA (2000). "Modulation of GABA-activated currents by phenazepam and its metabolites in isolated rat purkinje neurons". Neurophysiology. 32 (3): 192. doi:10.1007/BF02506568. ISSN 0090-2977. S2CID 32313668.
- ^ Golovenko NY, Larionov VB (2014). "Pharmacodynamical and Neuroreceptor Analysis of the Permeability of the Blood-Brain Barrier for Derivatives of 1,4-Benzodiazepine". Neurophysiology. 46 (3): 199–205. doi:10.1007/s11062-014-9429-2. ISSN 0090-2977. S2CID 33732669.
- ^ "3-hydroxyphenazepam". New Synthetic Drugs Database. Archived from the original on 2016-09-28. Retrieved 2016-05-30.
- ^ Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645. doi:10.1002/dta.2003. PMID 27366870.
- ^ Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). "Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam". Journal of Mass Spectrometry. 51 (11): 1080–1089. Bibcode:2016JMSp...51.1080M. doi:10.1002/jms.3840. PMID 27535017.
- ^ Manchester KR, Maskell PD, Waters L (March 2018). "Experimental versus theoretical log D7.4 , pKa and plasma protein binding values for benzodiazepines appearing as new psychoactive substances". Drug Testing and Analysis. 10 (8): 1258–1269. doi:10.1002/dta.2387. PMID 29582576. S2CID 31098917.